Why did Vertex Pharmaceuticals change its auditor?

The filing does not provide a specific reason for the change beyond the Audit Committee's decision to dismiss PwC and engage Ernst & Young LLP. However, it explicitly states there were no disagreements or reportable events with PwC, suggesting the change was not due to any accounting disputes or issues.

Will this change in auditor affect Vertex's financial statements?

A change in auditor typically does not directly alter past financial statements. However, a new auditor may bring a different perspective to current and future audits. The company has confirmed no disagreements with the outgoing auditor, and there's no indication of retrospective restatements mentioned in this filing.

Are there any concerns about auditor independence with Ernst & Young LLP?

No, the filing indicates that the Audit Committee reviewed auditor independence issues and existing commercial relationships with Ernst & Young LLP. They concluded that Ernst & Young LLP has no commercial relationships with the company that would impair their independence for the upcoming fiscal year.

What is the significance of the attached letter from PwC?

The letter from PwC, attached as Exhibit 16.1, is expected to confirm whether PwC agrees with Vertex Pharmaceuticals' statements in the 8-K regarding the circumstances of their dismissal. This letter serves as an independent verification of the company's assertions.

VRTX 8-K: Financial Events

Summary

Vertex Pharmaceuticals Incorporated (VRTX) announced a significant change in its auditing firm through this Form 8-K filed on September 7, 2005. The company's Audit Committee has dismissed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm, effective September 6, 2005. Concurrently, the Audit Committee has engaged Ernst & Young LLP to serve as the company's new independent auditor for the fiscal year ending December 31, 2005. This transition in auditors is a key event for investors as it can sometimes precede or coincide with changes in financial reporting or underlying business events. The filing explicitly states that there were no disagreements or reportable events with PwC during the past two fiscal years and up to the dismissal date. The company also confirmed that it had not consulted with Ernst & Young LLP on any matters that would be reportable under SEC regulations prior to their engagement. Investors should monitor future filings for any insights or disclosures that may arise from this change in auditing partners.

Key Highlights

1Vertex Pharmaceuticals has changed its independent registered public accounting firm.
2PricewaterhouseCoopers LLP (PwC) has been dismissed as the auditor.
3Ernst & Young LLP has been engaged as the new independent auditor for fiscal year 2005.
4The dismissal of PwC was effective September 6, 2005.
5The company states there were no disagreements with PwC on accounting principles or financial disclosures.
6There were no reportable events with PwC that would typically be disclosed.
7The Audit Committee reviewed auditor independence and concluded Ernst & Young LLP is independent.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Auditor Change (Sep 7, 2005)

Summary

Key Highlights

Frequently Asked Questions